Table 1.
The Norwegian APS-1 vaccine study
| Included subjects | APS-1 patients | Matched healthy controls | Elderly persons |
|---|---|---|---|
| N | 33 | 215 | 99 |
| %Female | 55 | 60 | 52 |
| Mean age | 46.0 | 44.5 | 86.0 |
| Range age | 19–76 | 23–82 | 65–99 |
| Total samples | 107 (range 1–6) | 703 (range 3–4) | 391 (range 3–4) |
| 1st vaccination | 33 | 215 | 99 |
| 2nd vaccination | 33 | 213 | 99 |
| 3rd vaccination | 26 | not included | not included |
| Samples before 1st vaccine | 33 | 0 | 0 |
| Interval 1st to 2nd dose (days) | 41 (range 21–83) | 21 | 21–22 |
| Interval 1st to 3rd dose (days) | 230 (range 82–382) | not included | not included |
| Samples after/at 2ndvaccination (pre-3rdvaccination): | |||
| Samples 3 weeks after 2nd vaccine | 12 | 213 | 99 |
| Samples 6–8 weeks after 2nd vaccine | 12 | 211 | 97 |
| Samples 5–6 months after 2nd vaccine | 15 | 304 | 99 |
| Samples >9 months after 2nd vaccine | 27 | 75 | 96 |
| Time points for vaccination 1–3 and sampling | Feb-Dec 2021 | Feb-Nov 2021 | Jan-Nov 2021 |